Insiders Trades
Moderna, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 04 Mar 2025.
Moderna, Inc.: what insiders have been doing
This page follows insider dealings at Moderna, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Cambridge, United States. The group dates from 2010. Its latest reported headcount is 5,800 employees (2024). In the past year (18 October 2025 to 18 October 2026), 83 filings came from 11 insiders.
The flow runs one way only: 14 sales worth €55.0M, from 6 insiders, and no purchase. The largest single trade was a sale of €9.5M by Bancel Stephane, published on 7 August 2026, equal to 0.014% of the market capitalisation.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 83 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Our records for Moderna, Inc. go back to 2021, with 2 purchases and 176 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.94 bn USD and net income of -2.82 bn USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
624
Thresholds
n/a
Buy Volume
€4M
2 ops. · all time
Sell Volume
€282M
176 ops. · all time
Who traded when
BuySaleStephen Hoge6 sales
Bancel Stephane1 buy4 sales
Hussain Abbas2 sales
James M. Mock2 sales
Afeyan Noubar1 sale
Sagan Paul1 buy
+1 other insider
Since the insiders bought
- +52.9%Entry US$35.21 · Close at T+365 US$53.83
- +52.9%Entry US$35.21 · Close at T+365 US$53.83
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Moderna, Inc. Hold (neutral), based on 18 analysts. Average price target: US$123.61.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,317 of 24,148 companies
34.0
score / 100
Value26
Quality42
FCF yld-2.2%
Earn yld-3.0%
EV/EBITDA·
ROE-39%
Gross mgn55%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$236.50
Analyst consensus
18 analystsHold
US$45.00Target US$123.61(-48%)US$200.00
Income statement
RevenueUS$1.9B
Gross profitUS$1.1B55% margin
EBITDA-US$2.5B-132% margin
Net income-US$2.8B-141.4% margin
Valuation
PER (forward)-53.3x
P/Book14.0x
Beta1.10
Balance sheet & cash
Market capUS$94.4B
Total debtUS$1.3B
Free Cash Flow-US$2.1B
Debt / Equity19%
Profitability & ownership
ROE-39.0%
ROA-13.3%
% insiders7.3%
% institutions80.4%
Last declaration on 16 October 2026
Declarations624 total
76,453 shares@ US$12.210.0010% mcap0.9% of flowCommon StockSEC:0001682852-26-000187:0
38,774 shares@ US$213.470.0088% mcap8.3% of flowCommon StockSEC:0001682852-26-000187:1
450 shares@ US$214.150.0001% mcap0.1% of flowCommon StockSEC:0001682852-26-000187:2
76,452 shares@ US$12.210.0010% mcap0.9% of flowCommon StockSEC:0001682852-26-000187:3
39,145 shares@ US$220.720.0092% mcap8.7% of flowCommon StockSEC:0001682852-26-000187:4
39,145 shares@ US$220.71870.0092% mcap10.7% of flowCommonSEC144:0001959173-26-007387
39,224 shares@ US$213.47950.0097% mcap11.6% of flowCommonSEC144:0001959173-26-007363
1,454 sharesCommon StockSEC:0001682852-26-000185:0
704 shares@ US$190.010.0002% mcap1.2% of flowCommon StockSEC:0001682852-26-000185:1
40,294 shares@ US$144.130.0072% mcap8.8% of flowCommon StockSEC:0001682852-26-000176:1
76,452 shares@ US$12.210.0012% mcap1.4% of flowCommon StockSEC:0001682852-26-000176:2
40,281 shares@ US$146.070.0073% mcap8.9% of flowCommon StockSEC:0001682852-26-000176:3
76,453 shares@ US$12.210.0012% mcap1.4% of flowCommon StockSEC:0001682852-26-000176:0
40,281 shares@ US$146.06660.0073% mcap8.9% of flowCommonSEC144:0001959173-26-006968
40,294 shares@ US$144.13430.0072% mcap8.8% of flowCommonSEC144:0001959173-26-006932
19,836 shares@ US$30.960.0008% mcap5.5% of flowCommon StockSEC:0001682852-26-000174:0
19,836 shares@ US$134.490.0033% mcap23.9% of flowCommon StockSEC:0001682852-26-000174:1
15,000 shares@ US$134.490.0025% mcap18.0% of flowCommon StockSEC:0001682852-26-000174:2
34,836 shares@ US$134.490.0058% mcap41.9% of flowCommonSEC144:0001959173-26-006846
11,797 sharesCommon StockSEC:0001682852-26-000169:0
11,797 sharesCommon StockSEC:0001682852-26-000172:0
5,704 shares@ US$148.870.0010% mcap33.3% of flowCommon StockSEC:0001682852-26-000169:1
5,704 shares@ US$148.870.0010% mcap7.6% of flowCommon StockSEC:0001682852-26-000172:1
2,475 sharesCommon StockSEC:0001682852-26-000165:0
1,197 shares@ US$140.340.0002% mcap1.5% of flowCommon StockSEC:0001682852-26-000165:1
25 of 624 declarations
About Moderna, Inc.
Moderna, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker MRNA. Headquartered in Cambridge, Massachusetts, United States, Moderna has become one of the best-known names in messenger RNA technology. Founded in 2010 and listed publicly in 2018, the company was built around a single strategic idea: using an mRNA platform to design, develop, and commercialize vaccines and therapeutics more rapidly than conventional drug-development models.
For investors, Moderna’s appeal lies in its platform economics. It is not a one-product biotech, but a technology-driven company seeking to industrialize mRNA design across multiple therapeutic areas. Its commercial portfolio now includes several approved products, notably Spikevax, its COVID-19 vaccine, mRESVIA, its RSV vaccine, and mNEXSPIKE, which was launched commercially in 2025. Beyond these marketed assets, Moderna is advancing a broader pipeline across infectious diseases and oncology, including programs in seasonal influenza, cytomegalovirus, RSV, and cancer. That pipeline diversification matters because the company is working to reduce dependence on the post-pandemic COVID franchise and build a more durable long-term revenue base.
Read moreShow less
From a competitive standpoint, Moderna remains a global leader in mRNA science, but it competes in a highly crowded and capital-intensive arena against large pharmaceutical and biotech peers with deep regulatory and commercial capabilities. Its core advantage is the combination of scientific platform breadth, clinical execution, and speed of development. At the same time, the company faces normalizing demand for COVID vaccines, pricing and volume pressure, and continued heavy investment requirements in research, manufacturing, and global commercialization.
Recent developments underscore this transition. Moderna’s 2025 and early 2026 disclosures point to expanding commercial traction, meaningful cost reductions, new phase 3 trial activity, and ongoing regulatory progress for future vaccines, including its seasonal flu program. The company has also highlighted geographic expansion efforts and international approvals or filings designed to broaden access outside the United States. For investors, Moderna should be viewed as a high-R&D, platform-oriented growth story whose valuation remains tied to the clinical, regulatory, and commercial success of its mRNA pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
